Maria Pyra1,2, Peter L Anderson3, Craig W Hendrix4, Renee Heffron1,2, Kenneth Mugwanya2, Jessica E Haberer5,6, Katherine K Thomas2, Connie Celum1,2,7, Deborah Donnell2,8, Mark A Marzinke4, Elizabeth A Bukusi2,9,10, Nelly R Mugo2,10, Stephen Asiimwe11, Elly Katabira12, Jared M Baeten1,2,7. 1. Department of Epidemiology. 2. Department of Global Health. 3. Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora. 4. Department of Medicine (Clinical Pharmacology), Johns Hopkins University, Baltimore. 5. Massachusetts General Hospital Global Health and Harvard Medical School. 6. Department of Medicine, Harvard Medical School, Boston. 7. Department of Medicine. 8. Vaccine and Infection Diseases and Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, USA. 9. Department of Obstetrics and Gynecology, University of Washington, Seattle. 10. Kenya Medical Research Institute (KEMRI). 11. Kabwohe Clinical Research Center. 12. Infectious Disease Institute, Makerere University, Uganda.
Abstract
OBJECTIVES: Pregnancy is a time of increased HIV acquisition risk and pregnancy reduces concentrations of antiretrovirals used for treatment. We assessed whether pregnancy lowers concentrations of tenofovir (TFV) and tenofovir-diphosphate (TFV-DP) among HIV-uninfected women using oral preexposure prophylaxis (PrEP). METHODS: We analyzed data from an open-label PrEP study, comparing concentrations of TFV in plasma and TFV-DP in dried blood spots (DBS) among 37 pregnant women and 97 nonpregnant women. Analyses controlled for adherence from daily electronic monitoring. RESULTS: The average plasma concentration of TFV among pregnant women was 34.7 ng/ml with 22.2 average recorded doses over the prior month versus 86.5 ng/ml with 23.1 doses among nonpregnant women. After controlling for adherence, TFV concentrations were 58% lower among pregnant women, a statistically significant difference of -50.4 ng/ml (95% CI -68.3 to -32.5). The average TFV-DP concentration was 450.3 fmol/punch among pregnant women and 636.7 fmol/punch among nonpregnant women. This difference was not statistically significant after adjusting for adherence; however, among those with quantifiable TFV-DP, concentrations were 27% lower during pregnancy [-202 fmol/punch (95% CI -384 to -19)]. Among participants with samples before and during pregnancy, there were significant decreases during pregnancy, controlling for adherence: -28.1 ng/ml TFV (95% CI -52.3 to -4.0) and -289.2 fmol/punch TFV-DP (95% CI -439.0 to -139.3). CONCLUSION: Consistent with studies among HIV-infected women on ART, we found TFV and TFV-DP concentrations were lower during pregnancy. There is no established TFV concentration threshold to achieve HIV prevention. Additional pharmacokinetic studies and studies of PrEP efficacy in pregnancy are needed.
OBJECTIVES: Pregnancy is a time of increased HIV acquisition risk and pregnancy reduces concentrations of antiretrovirals used for treatment. We assessed whether pregnancy lowers concentrations of tenofovir (TFV) and tenofovir-diphosphate (TFV-DP) among HIV-uninfectedwomen using oral preexposure prophylaxis (PrEP). METHODS: We analyzed data from an open-label PrEP study, comparing concentrations of TFV in plasma and TFV-DP in dried blood spots (DBS) among 37 pregnant women and 97 nonpregnant women. Analyses controlled for adherence from daily electronic monitoring. RESULTS: The average plasma concentration of TFV among pregnant women was 34.7 ng/ml with 22.2 average recorded doses over the prior month versus 86.5 ng/ml with 23.1 doses among nonpregnant women. After controlling for adherence, TFV concentrations were 58% lower among pregnant women, a statistically significant difference of -50.4 ng/ml (95% CI -68.3 to -32.5). The average TFV-DP concentration was 450.3 fmol/punch among pregnant women and 636.7 fmol/punch among nonpregnant women. This difference was not statistically significant after adjusting for adherence; however, among those with quantifiable TFV-DP, concentrations were 27% lower during pregnancy [-202 fmol/punch (95% CI -384 to -19)]. Among participants with samples before and during pregnancy, there were significant decreases during pregnancy, controlling for adherence: -28.1 ng/ml TFV (95% CI -52.3 to -4.0) and -289.2 fmol/punch TFV-DP (95% CI -439.0 to -139.3). CONCLUSION: Consistent with studies among HIV-infectedwomen on ART, we found TFV and TFV-DP concentrations were lower during pregnancy. There is no established TFV concentration threshold to achieve HIV prevention. Additional pharmacokinetic studies and studies of PrEP efficacy in pregnancy are needed.
Authors: Angela P H Colbers; David A Hawkins; Andrea Gingelmaier; Kabamba Kabeya; Jürgen K Rockstroh; Christopher Wyen; Katharina Weizsäcker; S Tariq Sadiq; Jelena Ivanovic; Carlo Giaquinto; Graham P Taylor; José Moltó; David M Burger Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: B M Best; S Burchett; H Li; A Stek; C Hu; J Wang; E Hawkins; M Byroads; D H Watts; E Smith; C V Fletcher; E V Capparelli; M Mirochnick Journal: HIV Med Date: 2015-05-11 Impact factor: 3.180
Authors: Patricia M Flynn; Mark Mirochnick; David E Shapiro; Arlene Bardeguez; John Rodman; Brian Robbins; Sharon Huang; Susan A Fiscus; Koen K A Van Rompay; James F Rooney; Brian Kearney; Lynne M Mofenson; D Heather Watts; Patrick Jean-Philippe; Barbara Heckman; Edwin Thorpe; Amanda Cotter; Murli Purswani Journal: Antimicrob Agents Chemother Date: 2011-09-06 Impact factor: 5.191
Authors: Nelly R Mugo; Ting Hong; Connie Celum; Deborah Donnell; Elizabeth A Bukusi; Grace John-Stewart; Jonathan Wangisi; Edwin Were; Renee Heffron; Lynn T Matthews; Susan Morrison; Kenneth Ngure; Jared M Baeten Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272
Authors: Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson Journal: AIDS Res Hum Retroviruses Date: 2015-10-15 Impact factor: 2.205
Authors: Sheree R Schwartz; Jean Bassett; Charles B Holmes; Nompumelelo Yende; Rebecca Phofa; Ian Sanne; Annelies Van Rie Journal: J Int AIDS Soc Date: 2017-03-08 Impact factor: 5.396
Authors: Jillian Pintye; John Kinuthia; Felix Abuna; Kenneth Mugwanya; Harison Lagat; Julia C Dettinger; Daniel Odinga; Joseph Sila; Peter L Anderson; Grace John-Stewart; Jared M Baeten Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: Lisa L Abuogi; Jose Castillo-Mancilla; Karen Hampanda; Kevin Owuor; Tobias Odwar; Maricianah Onono; Anna Helova; Janet M Turan; Peter L Anderson Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Jillian Pintye; Dvora L Joseph Davey; Anjuli D Wagner; Grace John-Stewart; Rachel Baggaley; Linda-Gail Bekker; Connie Celum; Benjamin H Chi; Thomas J Coates; Allison K Groves; Jessica E Haberer; Renee Heffron; John Kinuthia; Lynn T Matthews; James A McIntyre; Dhayendre Moodley; Lynne M Mofenson; Nelly Mugo; Andrew Mujugira; Landon Myer; Steven Shoptaw; Lynda Stranix-Chibanda; Jared M Baeten Journal: Lancet HIV Date: 2020-08 Impact factor: 12.767
Authors: Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Jim Aizire; Kristina M Brooks; Mark Mirochnick; Patricia M Flynn; Kevin Butler; Jennifer J Kiser; George K Siberry; Terry Fenton; Mae Cababasay; Mary G Fowler Journal: J Acquir Immune Defic Syndr Date: 2020-02-01 Impact factor: 3.771
Authors: Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick Journal: Expert Opin Drug Metab Toxicol Date: 2020-03-17 Impact factor: 4.936